Default company panoramic image
223aadc6 e8b3 447d 9a8e d18baf99fa39

Aurora Oncology, Inc.

Aurora Oncology develops targeted biologics to satisfy the unmet need of improved efficacy and safety of bladder cancer therapy.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Aurora, CO, USA
  • Currency USD
  • Founded November 2011
  • Employees 2
  • Website --

Company Summary

Aurora Oncology is focused on the development and commercialization of unique biologics for the treatment of superficial bladder cancer. DAB389EGF and Nano-EGFR work by targeting specific receptors on the surface of cancer cells. Nano-EGFR also allows for imaging of bladder cancer in the patient resulting in the potential for targeted therapy. Both of these products are poised to enter clinical development.

Team

  • Default avatar
    Mike Glode, M.D.
    Founder and President

    Professor of Medicine (Medical Oncology), University of Colorado School of Medicine

  • Default avatar
    Tom Flaig, M.D.
    Founder and VP-EGFR Targets

    Associate Professor of Medicine (Medical Oncology), University of Colorado School of Medicine

  • Default avatar
    Dan Theodorescu, M.D.
    Founder and VP-Ral Targets

    Head, University of Colorado Comprehensive Cancer Center;
    Professor of Surgery and Medicine (Medical Oncology), University of Colorado School of Medicine

Advisors

  • Default avatar
    Brent Fassett, Cooley LLP
    Lawyer
    Unconfirmed
    Default avatar
    N/A
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    N/A
    Unconfirmed